Damini Sant

SAT668 Can We Treat Osteoporosis, Obesity And Neurodegeneration With A Single FSH-blocking Drug?

Anusha Pallapati, Judit Gimenez–Roig, Satish V. Rojekar, Funda Korkmaz et autres

Abstract Disclosure: A.R. Pallapati: None. J. Gimenez-Roig: None. S. Rojekar: None. F. Korkmaz: None. D. Sant: None. O. Barak: None. F. Sultana: None. O. Moldavski: None. A. Gumerova: None. H.S. Kannangara: None. U. Cheliadinova: None. C.J. Rosen: None. J.N. Caminis: None. M. …

us, de (code pays fourni par la source)

SAT669 Development And Biophysical Characterization Of A Humanized FSH-blocking Monoclonal Antibody Therapeutic Formulated At An Ultra-high Concentration

Satish V. Rojekar, Anusha Pallapati, Judit Gimenez–Roig, Damini Sant et autres

Abstract Disclosure: S. Rojekar: None. A.R. Pallapati: None. J. Gimenez–Roig: None. D. Sant: None. S. Gera: None. F. Korkmaz: None. F. Sultana: None. O. Barak: None. O. Moldavski: None. U. Cheliadinova: None. A. Gumerova: None. S. Miyashita: None. H.S. Kannangara: None. T. …

us, de (code pays fourni par la source)

Development and biophysical characterization of a humanized FSH–blocking monoclonal antibody therapeutic formulated at an ultra-high concentration

Satish V. Rojekar, Anusha Pallapati, Judit Gimenez–Roig, Funda Korkmaz et autres

Highly concentrated antibody formulations are oftentimes required for subcutaneous, self-administered biologics. Here, we report the development of a unique formulation for our first-in-class FSH-blocking humanized antibody, MS-Hu6, which we propose to move to the clinic for osteoporosis, obesity, and Alzheimer’s disease. The …

us (code pays fourni par la source)

Author response: Development and biophysical characterization of a humanized FSH–blocking monoclonal antibody therapeutic formulated at an ultra-high concentration

Satish V. Rojekar, Anusha Pallapati, Judit Gimenez–Roig, Funda Korkmaz et autres

us (code pays fourni par la source)

Development and Biophysical Characterization of a Humanized FSH–Blocking Monoclonal Antibody Therapeutic Formulated at an Ultra–High Concentration

Satish V. Rojekar, Anusha Pallapati, Judit Gimenez–Roig, Funda Korkmaz et autres

ABSTRACT Highly concentrated antibody formulations are oftentimes required for subcutaneous, self-administered biologics. Here, we report the creation of a unique formulation for our first–in– class FSH–blocking humanized antibody, MS-Hu6, which we propose to move to the clinic for osteoporosis, obesity, and Alzheimer’s …

us (code pays fourni par la source)

Optimizing a therapeutic humanized follicle‐stimulating hormone–blocking antibody formulation by protein thermal shift assay

Damini Sant, Satish V. Rojekar, Sakshi Gera, Anusha Pallapati et autres

Abstract Biopharmaceutical products are formulated using several Food and Drug Administration (FDA) approved excipients within the inactive ingredient limit to maintain their storage stability and shelf life. Here, we have screened and optimized different sets of excipient combinations to yield a thermally …

us, gb (code pays fourni par la source)

PMON51 A Single Multipurpose FSH–Blocking Therapeutic for Osteoporosis, Obesity and Alzheimer's Disease

Funda Korkmaz, Tan‐Chun Kuo, Sakshi Gera, Damini Sant et autres

Abstract Pharmacological and genetic studies over the past decade suggest that FSH is an actionable target for diseases affecting millions, notably osteoporosis, obesity and Alzheimer's disease (AD). Blocking FSH action prevents bone loss (1, 2), fat and energy metabolism (3) and AD–like …

FSH-blocking therapeutic for osteoporosis

Sakshi Gera, Tan‐Chun Kuo, Anisa Azatovna Gumerova, Funda Korkmaz et autres

Pharmacological and genetic studies over the past decade have established the follicle-stimulating hormone (FSH) as an actionable target for diseases affecting millions, namely osteoporosis, obesity, and Alzheimer’s disease. Blocking FSH action prevents bone loss, fat gain, and neurodegeneration in mice. We recently …

gb, us (code pays fourni par la source)

Author response: FSH-blocking therapeutic for osteoporosis

Sakshi Gera, Tan‐Chun Kuo, Anisa Azatovna Gumerova, Funda Korkmaz et autres

The first-in-class, humanized, epitope-specific FSH-blocking antibody MS-Hu6 is efficacious, durable, and manufacturable, and is therefore poised for further development towards future testing in human trials for osteoporosis, obesity, dyslipidemia and neurodegeneration.

gb, us (code pays fourni par la source)

A Single Multipurpose FSH–Blocking Therapeutic for Osteoporosis and Obesity

Sakshi Gera, Tan‐Chun Kuo, Funda Korkmaz, Damini Sant et autres

ABSTRACT Pharmacological and genetic studies over the past decade have established FSH as an actionable target for diseases affecting millions, notably osteoporosis, obesity and Alzheimer’s disease (AD). Blocking FSH action prevents bone loss, fat gain and AD–like features in mice. We recently …

us (code pays fourni par la source)

FSH blockade improves cognition in mice with Alzheimer’s disease

Jing Xiong, Seong Su Kang, Zhihao Wang, Xia Liu et autres

us, cn (code pays fourni par la source)

First-in-class humanized FSH blocking antibody targets bone and fat

Sakshi Gera, Damini Sant, Shozeb M Haider, Funda Korkmaz et autres

Significance We report the development and characterization of a first-in-class humanized antibody to follicle-stimulating hormone (FSH). We have shown previously that blocking FSH action on its receptor increases bone mass, reduces body fat, and enhances energy expenditure. Furthermore, FSH has been reported …

us, gb, cn (code pays fourni par la source)